Omalizumab, an anti-IgE monoclonal antibody, is increasingly being used in diseases other than allergic asthma. We report on the successful long-term management of refractory chronic urticaria in 2 patients using low-dose omalizumab.
Manteinance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria.
ROMANO, Ciro Pasquale;GIUNTA, Riccardo;LUCIVERO, Giacomo
2010
Abstract
Omalizumab, an anti-IgE monoclonal antibody, is increasingly being used in diseases other than allergic asthma. We report on the successful long-term management of refractory chronic urticaria in 2 patients using low-dose omalizumab.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
